Independent
Tenure on this board
2.5 yrs
Also a director at
Biogen Inc (BIIB)
Meeting calendar
ABSI · Annual meeting · Thursday, June 4, 2026
Absci Corp
2 nominees · 2 ballot items.
Elect two Class II directors (Prof Sir Menelas Pangalos, Ph.D. and Daniel Rabinovitsj) and ratify Ernst & Young LLP as Absci Corporation's independent registered public accounting firm for the fiscal year ending December 31, 2026; the board recommends voting FOR both proposals.
Market cap
$1.3B
1Y TSR
+238.0%
Board grade
C+
Record date
Apr 7, 2026
Filing
DEF 14A
Meeting concluded · Jun 4, 2026
Follow how the vote landed and what changed on Absci Corp’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot2
- 1
Election of Class II Directors
ManagementBoard: FORElect two Class II directors, Prof Sir Menelas Pangalos, Ph.D. and Daniel Rabinovitsj, each to serve a three‑year term expiring at the 2029 annual meeting (until their successors are duly elected and qualified, or earlier death, resignation or removal).
- 2
Ratification of the Appointment of Ernst & Young LLP as Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2026
ManagementBoard: FORRatify the audit committee's appointment of Ernst & Young LLP as Absci Corporation’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
Director elections
Nominees on the ballot2
Independent
Tenure on this board
3.7 yrs
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | ARK Investment Management LLC | 8.8% | 13,726,169 | $41M |
| 2 | FMR LLC | 8.1% | 12,607,901 | $38M |
| 3 | FMR LLC | 6.4% | 9,943,096 | $30M |
| 4 | Redmile Group, LLC | 5.3% | 8,253,316 | $25M |
| 5 | STATE STREET CORP | 4.7% | 7,324,858 | $22M |
| 6 | BlackRock, Inc. | 3.9% | 6,009,172 | $18M |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 3.8% | 5,886,640 | $18M |
| 8 | ADVANCED MICRO DEVICES INC | 3.7% | 5,714,285 | $17M |
| 9 | BlackRock, Inc. | 2.6% | 4,113,834 | $12M |
| 10 | Woodline Partners LP | 2.1% | 3,300,169 | $10M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Absci Corp’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Avanos Medical IncAVNS
Special meeting·Jul 22, 2026·$1.2B
Anaptysbio IncANAB
Annual meeting·Aug 11, 2026·$1.7B
Trulieve Cannabis CorpTRLV
Special meeting·Aug 5, 2026·$1.7B
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$723M
Indaptus Therapeutics IncINDP
Annual meeting·Aug 10, 2026·$287M
Prestige Consumer Healthcare IncPBH
Annual meeting·Aug 4, 2026·$2.4B
Reference
Frequently asked questions
- When is the Absci Corp 2026 annual meeting?
- Absci Corp (ABSI) holds its 2026 annual shareholder meeting on Thursday, June 4, 2026.
- What is the record date for the Absci Corp 2026 meeting?
- The record date for the Absci Corp 2026 meeting is Tuesday, April 7, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Absci Corp's 2026 meeting?
- The board is presenting 2 director nominees at the Absci Corp 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Absci Corp 2026 meeting?
- Shareholders will vote on 2 proposals at the Absci Corp 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.